Ramucirumab: targeting angiogenesis in the treatment of gastric cancer

Area of Science:

• Oncology
• Pharmacology
• Cancer Biology

Background:

• Gastroesophageal cancer causes over 1 million deaths annually, with limited options for advanced stages.
• Angiogenesis, the formation of new blood vessels, is a key process in cancer growth and a viable therapeutic target.
• Ramucirumab is a monoclonal antibody that inhibits vascular endothelial growth factor receptor 2 (VEGFR-2).

Purpose of the Study:

• To evaluate the efficacy and safety of ramucirumab in patients with advanced gastroesophageal cancer.
• To assess ramucirumab as a single agent and in combination with paclitaxel.

Main Methods:

• Two large randomized trials, REGARD and RAINBOW, were conducted.
• Patients had advanced gastroesophageal cancer and had previously received fluoropyrimidine- or platinum-containing chemotherapy.
• Ramucirumab was administered as a single agent or in combination with paclitaxel.

Main Results:

• Ramucirumab demonstrated efficacy in both single-agent and combination therapy settings.
• Patients treated with ramucirumab and paclitaxel showed increased rates of neutropenia.
• Hypertension was an observed side effect, consistent with anti-angiogenic agents.

Conclusions:

• Ramucirumab is an effective treatment for advanced gastroesophageal cancer.
• The drug is US FDA approved for patients progressing after standard chemotherapy.
• Monitoring for side effects like neutropenia and hypertension is important.